Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Trump Says Anthropic No Longer Seen as National Security Threat 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
TEL AVIV, Israel, Feb. 02, 2016 -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that it will report its financial results for the fourth quarter and fiscal year ended December 31, 2015 before the market open, and will host a corporate update conference call and webcast on Wednesday, February 17 at 8:30 am Eastern Time.
| Conference Call & Webcast | |
| Wednesday, February 17, 2016 @ 8:30am Eastern Time | |
| Domestic: | 855-469-0611 |
| International: | 484-756-4341 |
| Passcode: | 34475008 |
| Webcast: | http://www.alcobra-pharma.com/events.cfm |
| Replays available through March 2, 2016 | |
| Domestic: | 855-859-2056 |
| International: | 404-537-3406 |
| Passcode: | 34475008 |
About Alcobra
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and FXS. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 [email protected] Media Inquiries Sam Brown, Inc. Mike Beyer 773-463-4211 [email protected] Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661 [email protected]
